MedPath

Tagged News

Study Reveals Age-Specific Disease Burdens in Pediatric and Adolescent Atopic Dermatitis Patients

Real World Evidence
  • A cross-sectional study of 772 pediatric and adolescent patients with moderate-to-severe atopic dermatitis revealed distinct age-related differences in disease burden and treatment patterns.
  • Adolescent patients (12-17 years) experienced significantly higher psychological distress, including anxiety, embarrassment, and social impacts, compared to younger children (0-11 years).
  • Pediatric patients were more likely to report sleep disruption as their most bothersome symptom, while adolescents faced greater emotional burden related to the visual aspects of their condition.
  • The findings highlight the need for age-specific treatment strategies and improved therapeutic options for both age groups in the evolving atopic dermatitis treatment landscape.

Real-World Safety Analysis Reveals Increased Kidney and Liver Toxicity with Pembrolizumab-Chemotherapy Combination in Lung Cancer

Real World Evidence
  • A comprehensive analysis of 8,314 lung cancer patients from the FAERS database revealed that pembrolizumab combined with pemetrexed and platinum chemotherapy significantly increases the risk of renal and hepatobiliary disorders compared to chemotherapy alone.
  • The combination therapy demonstrated a delayed onset of adverse events, with most occurring within three months versus six weeks for chemotherapy alone, requiring enhanced monitoring protocols during the initial treatment period.
  • Gender and age disparities emerged as critical factors, with elderly patients (≥65 years) experiencing higher rates of blood disorders and kidney problems, while female patients showed increased susceptibility to nephrotoxicity across both treatment regimens.
  • Despite increased toxicity risks, the safety profile remains within acceptable ranges, with common adverse events including anemia, neutropenia, and thrombocytopenia being similar between treatment approaches.

Long-Term Follow-Up of TRANSFORM Trial Shows Sustained Benefits of Liso-Cel CAR T-Cell Therapy in Relapsed LBCL

CAR-TOncologyReal World Evidence
  • Three-year follow-up data from the phase 3 TRANSFORM trial demonstrates lisocabtagene maraleucel (liso-cel) significantly improved event-free survival with a median of 29.5 months versus 2.4 months with standard of care in relapsed large B-cell lymphoma.
  • Liso-cel showed impressive efficacy with an 87% overall response rate and 74% complete response rate, while maintaining a favorable safety profile with lower rates of cytokine release syndrome and neurotoxicity compared to axicabtagene ciloleucel.
  • The study revealed that patients who received liso-cel as second-line therapy had substantially better outcomes than those who crossed over after standard chemotherapy, emphasizing the importance of early CAR T-cell intervention.

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351CompletedPhase 3
Celgene
Posted 10/23/2018

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466CompletedPhase 3
Kite, A Gilead Company
Posted 1/25/2018

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103CompletedPhase 2
Juno Therapeutics, a Subsidiary of Celgene
Posted 7/27/2018

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

NCT04531046Active, Not RecruitingPhase 2
The Lymphoma Academic Research Organisation
Posted 3/10/2021

Mallinckrodt to Present Five Clinical Studies on TERLIVAZ for Hepatorenal Syndrome at DDW 2025

Real World EvidenceRare Disease
  • Mallinckrodt will present five clinical analyses of TERLIVAZ (terlipressin) for hepatorenal syndrome with rapid reduction in kidney function (HRS-AKI) at Digestive Disease Week 2025 in San Diego.
  • TERLIVAZ is the first and only FDA-approved treatment for improving kidney function in adults with HRS-AKI, a rare and life-threatening condition affecting approximately 42,000 Americans annually.
  • The presentations will include real-world evidence on treatment outcomes in various patient populations, including those on transplant waitlists and with alcohol-associated liver disease.

University of Glasgow and myDNA Partner to Advance Pharmacogenomics Integration in NHS Healthcare

Precision MedicineReal World Evidence
  • The University of Glasgow's Living Laboratory for Precision Medicine has partnered with myDNA to generate real-world evidence supporting pharmacogenomics adoption in healthcare systems.
  • The collaboration aims to assess clinical benefits and cost-effectiveness of personalized drug selection based on individual genetic profiles, moving away from traditional "one-size-fits-all" medication approaches.
  • The partnership will focus on integrating pharmacogenomics into everyday clinical practice across Scotland and the NHS, with potential global impact for healthcare systems worldwide.
  • The initiative seeks to improve medication safety and efficacy for patients while contributing to significant cost savings for healthcare systems through precision medicine strategies.

HSV-1 Infection Linked to 80% Increased Alzheimer's Risk in Large-Scale Claims Analysis

Real World Evidence
  • A matched case-control study of 344,628 Alzheimer's disease patients found that HSV-1 infection was associated with an 80% increased risk of developing the neurodegenerative condition.
  • Laboratory research revealed that HSV-1 triggers tau protein accumulation in brain cells, initially serving as a protective immune response before potentially contributing to neurodegeneration.
  • Patients with HSV-1 who received antiherpetic treatment showed a 17% reduced risk of developing Alzheimer's disease compared to untreated individuals.

Real-World Evidence Validates Proenkephalin A 119-159 as Superior Kidney Function Biomarker in Critical Care

Real World Evidence
  • A comprehensive real-world study of over 4,000 ICU patients demonstrates that Proenkephalin A 119-159 (penKid) significantly outperforms traditional creatinine markers in detecting acute kidney injury and assessing kidney function.
  • PenKid successfully identifies high-risk patients at ICU admission, particularly those with normal serum creatinine levels, and predicts AKI development within 24-48 hours more accurately than conventional methods.
  • The biomarker maintains its diagnostic effectiveness during renal replacement therapy, providing dynamic insights into kidney recovery that could optimize treatment duration and reduce unnecessary interventions.
  • International recognition from Mayo Clinic researchers confirms penKid's clinical value, highlighting its ability to detect rapid kidney function changes and predict major adverse kidney events in critically ill patients.

Real-World Evidence Oncology Market Projected to Reach $3.51 Billion by 2035 with 14.7% CAGR

Real World EvidenceOncologyAIPrecision Medicine
  • The real-world evidence oncology solutions market is projected to grow from $893 million in 2025 to $3.51 billion by 2035, representing a compound annual growth rate of 14.7%.
  • Market growth is driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing global cancer incidence, and advancements in data analytics and AI technologies.
  • North America is expected to hold the largest market share in 2025, while the Asia-Pacific region is projected to experience the fastest growth during the forecast period.
  • The datasets segment is expected to account for the largest market share, while pharmaceutical, biotechnology, and medical device companies represent the primary end-user segment.

Decade-Long UK Registry Reveals Key Insights into Idiopathic Pulmonary Fibrosis Management and Future Directions

Real World Evidence
  • The British Thoracic Society's analysis of the UK Idiopathic Pulmonary Fibrosis Registry provides the first comprehensive long-term data on over 5,000 IPF cases across 64 UK hospitals.
  • Key findings include significant diagnostic delays with 60% of patients experiencing symptoms for over a year before their first clinic visit, and a shift in antifibrotic treatment preferences from pirfenidone to nintedanib after 2017.
  • Experts are now advocating for a shift from consensus-based criteria toward personalized, data-driven approaches for early diagnosis and treatment, with initiatives like the global PRIME-PPF study aiming to refine risk stratification.

Real-World Studies Confirm Bevacizumab Biosimilars Deliver Cost Savings and Equivalent Clinical Outcomes in Metastatic Colorectal Cancer

Monoclonal AntibodyReal World EvidenceOncology
  • A Canadian population-based study found bevacizumab biosimilars Mvasi and Zirabev provided $6,379 CAD in annual cost savings per patient compared to originator Avastin while maintaining equivalent survival outcomes in metastatic colorectal cancer.
  • An Indian real-world analysis of 944 patients demonstrated comparable progression-free survival and overall survival between bevacizumab biosimilars and the reference product in first-line and second-line treatment settings.
  • Both studies support the cost-effectiveness and clinical equivalence of bevacizumab biosimilars, providing evidence for healthcare policy decisions and building confidence among oncologists treating metastatic colorectal cancer.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.